EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Raphael Pharmaceutical's Enterprise Value is $28.24 Mil.
Raphael Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.05 Mil. Therefore, Raphael Pharmaceutical's EV-to-FCF for today is -627.47.
The historical rank and industry rank for Raphael Pharmaceutical's EV-to-FCF or its related term are showing as below:
RAPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -627.47 Med: 0 Max: 0
Current: -627.47
RAPH's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 20.11
vs RAPH: -627.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Raphael Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Raphael Pharmaceutical's share price for today is $1.40.
Raphael Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raphael Pharmaceutical EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Raphael Pharmaceutical's EV-to-FCF falls into.
Raphael Pharmaceutical's current Enterprise Value is $28.24 Mil.
Raphael Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raphael Pharmaceutical (RAPH) has a EV-to-FCF of -627.47 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's EV-to-FCF too high?
Raphael Pharmaceutical's current EV-to-FCF is -627.47. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's EV-to-FCF compare to TXMD and AYTU?
Raphael Pharmaceutical's EV-to-FCF of -627.47 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 20.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Raphael Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raphael Pharmaceutical's current EV-to-FCF is -627.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current EV-to-FCF of -627.47. The current EV-to-FCF is -627.47. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current EV-to-FCF is -627.47 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score
Get the complete analysis for RAPH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPH has been successfully added to your 
